Clinical Trials Update

Cetuximab Saratolacan Approved in Japan for the Treatment of Unresectable Locally Advanced and Recurrent...

Japan’s Ministry of Health, Labour and Welfare has approved cetuximab saratolacan sodium (previously known as RM-1929; Akalux® IV Infusion...

ESMO 2020: Study Shows Meaningful Clinical Activity with Tisotumab Vedotin in Cervical Cancer

Tisotumab vedotin, an investigational agent is being developed by Seattle Genetics and Genmab, shows meaningful clinical activity as monotherapy...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27% ORR

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics). This is the conclusion from an analysis...

Study Meets Primary Endpoint: Enfortumab Vedotin Significantly Improves Overall Survival in Urothelial Cancer

A phase III trial of enfortumab vedotin (enfortumab vedotin-ejfv; Padcev®; Seattle Genetics/Astellas) met its primary endpoint of overall survival...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain Cancer

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in Ovarian Cancer

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an...

First Patients Dosed in Phase II Study of Patritumab Deruxtecan in HER3 Expressing Advanced...

A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as...

Merck & Co and Seattle Genetics Sign Exclusive Licensing and Co-Development Agreement

Merck & Co and Seattle Genetics have signed an exclusive licensing and co-developing agreement to globally develop and commercialize...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on...
Featured Image: Scientist in Biomedical Laboratory. Courtesy 2019 Fotolia. used with permission.

Phase I clinical study of SBT6050 Initiated

Activation of toll-like receptor 8 (TLR8) enhances natural killer(NK-) cell activation, increases antibody-dependent cell-mediated cytotoxicity and induces Th1 polarizing...

X